Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBSTITUTE: Basal Bolus Therapy (Insulin Glargine + Insulin Glulisine) in T1DM
NCT01204593Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2010
- Primary completion
- Jan 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine and insulin glulisine in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Primary endpoint: Change in hemoglobin A1c at 24 weeks. Started Nov 2010; status: completed.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01204593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204593.